Category Archives: Blog

Enlarged prostate treatment going to the dogs?

dogsA new treatment for enlarged prostates in dogs may actually help their human masters.

A small study successfully treated 20 dogs having an enlarged prostate with a non-surgical treatment. Treatment was pulsed, electromagnetic field therapy (PEMF) given through a medical device held above the skin where the prostate is located. Therapy was given twice a day for three weeks. Each session lasted about five minutes.

On average, the dogs’ prostate reduced in size by 57 percent during the three-week treatment span with no side effects such as a reduced libido or testosterone levels. The study was published in the journal,  The Prostate.

PEMF produced both an electrical and magnetic field. It’s considered a complementary therapy — not mainstream medicine.

Citrus fruits offer protection against bladder cancer.

Citrus fresh fruit isolated on a white backgroundEating more citrus fruits may reduce the risk of bladder cancer according to an analysis published by a Chinese researcher. The analysis, which examined the pooled data from 14 studies, found that people who consumed the most citrus fruit had 15% decreased risk of bladder cancer compared to those with the lowest intake. The analysis was published online in the International Journal of Food Sciences and Nutrition.

Citrus fruits contain many cancer-fighting agents including vitamin C, carotenoids and flavonoids. Citrus fruits include oranges, lemons, limes and grapefruit. Grapefruit, however, can interact with some medications and cause adverse reactions. Consult with your physician.

Walking benefits kidney disease patients

Taiwanese researchers discovered that walking might prolong the lives of kidney disease patients and reduce their chance of needing dialysis. Although a minimal amount of walking — such as a 30-minute stroll once a week — may be helpful, longer and more frequent walks appear to be more beneficial.

Researchers tracked 6,300 Taiwanese patients with chronic kidney disease (CKD) for about 1.3 years. Patients who walked reduced their risk of dying by a third and were 21 percent less likely to require dialysis or a kidney transplant when compared to those who did not walk. The study was published online in the Clinical Journal of the American Society of Nephrology.

Another Prostate Cancer Clue

Australian researchers have discovered biomarkers in seminal fluid that indicated the presence of prostate cancer. Biomarkers are specific molecules found in blood and other body fluids. They indicate normal or abnormal conditions. However, a prostate cancer biomarker detects prostate cancer.

The small study conducted by the University of Adelaide found that men with certain molecules called microRNAs had prostate cancer, and that men who had one specific type of microRNA called miR-200b were likely to have aggressive cancer.

Results were published in the journal Endocrine-Related Cancer.

National Cancer Institute Releases Early, Prostate-Cancer Study Findings

Two-drug combo extends survival in advanced, prostate cancer patients.

Men with advanced prostate cancer survived longer on a combination of two types of drugs than the standard, single treatment approach, reports a federally sponsored study. The standard practice has been to first treat men with hormone therapy to suppress testosterone and then use the chemotherapy drug docetaxel when cancer progresses.

A medical oncologist at the Harvard-affiliated Dana-Farber Cancer Institute in Boston led the 790-patient trial, which found that 69 percent of the men who started with the combination therapy where alive after three years, compared with 52.5 percent who initially were on hormone therapy. The survival advantage was so significant that the NCI, which funded the study, decided to release its finding early.

Men whose prostate cancer spread to at least four locations in bone or to a major organ were the most likely to benefit from the combination therapy.

Make An Appointment

(314) 843-8000

South County Urological
12345 West Bend Drive Suite 200
St. Louis, MO 63128